SCHEMBL25754594

SCHEMBL25754594

CC#CC(=O)CCCCOCCN1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPK1 P28482 1/20 0.42
HRH3 Q9Y5N1 5/20 0.40
ALDH1A1 P00352 7/20 0.39
THRB P10828 3/20 0.39
KDM4E B2RXH2 2/20 0.39
THRA P10827 1/20 0.39
LMNA P02545 2/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
ADRA2C P18825 1/20 0.39
DRD4 P21917 1/20 0.39
ACHE P22303 1/20 0.39
SLC6A2 P23975 1/20 0.39
HRH2 P25021 1/20 0.39
HTR2A P28223 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754610 0.96 HRH3 (0.42) CYP1A2SMN1; SMN2MAPK1HRH3ALDH1A1
SCHEMBL25754615 0.96 HRH3 (0.42) CYP1A2SMN1; SMN2MAPK1HRH3ALDH1A1
SCHEMBL25754613 0.90 HRH3 (0.42) CYP1A2SMN1; SMN2MAPK1HRH3ALDH1A1
SCHEMBL25754592 0.86 ALDH1A1 (0.50) CYP1A2SMN1; SMN2MAPK1HRH3ALDH1A1
SCHEMBL25754752 0.85 SMN1; SMN2 (0.38) CYP1A2SMN1; SMN2MAPK1HRH3ALDH1A1
SCHEMBL25754612 0.83 HRH3 (0.43) HRH3ALDH1A1KDM4EHRH1KCNH2
SCHEMBL25754605 0.83 HRH3 (0.43) HRH3ALDH1A1KDM4EHRH1KCNH2
SCHEMBL25754758 0.83 HRH3 (0.39) CYP1A2SMN1; SMN2MAPK1HRH3KDM4E
SCHEMBL25754731 0.81 KDM4E (0.39) CYP1A2SMN1; SMN2MAPK1HRH3ALDH1A1
SCHEMBL25754602 0.80 HRH2 (0.34) ALDH1A1HRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 CYP1A2 3367/4885SMN1; SMN2 2462/4885MAPK1 3542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.